In a study of 2,000 cancer patients, hydroxychloroquine showed no clinical benefit. Remdesivir was associated with a lower mortality risk but only certain groups of patients had access to it. Cancer patients also showed a higher risk of dying within 30 Days of receiving a coronavirus diagnosis.